Dr. Hassan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 216-445-9365
Summary
- Dr. Khaled Hassan is an oncologist in Cleveland, OH and is affiliated with multiple hospitals in the area, including Michigan Medicine, Veterans Affairs Ann Arbor Healthcare System, and Cleveland Clinic. He received his medical degree from Kursk State Medical University and has been in practice 19 years. He specializes in hematologic oncology and thoracic cancer and is experienced in thoracic oncology.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2006 - 2009
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 2003 - 2006
Kursk State Medical UniversityClass of 1998
Certifications & Licensure
OH State Medical License 2014 - 2026
MI State Medical License 2007 - 2020- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer.Marko Velimirovic, Matthew Brignola, Emily Chheng, Michael Smith, Khaled A Hassan
Current Treatment Options in Oncology. 2024-10-01 - MUC1-C: The Occam Razor of Osimertinib Resistance?Anirudh Yalamanchali, Khaled A Hassan
Journal of Thoracic Oncology. 2024-03-01 - 6 citationsClinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab.Lukas Delasos, Wei Wei, Khaled A Hassan, Nathan A Pennell, Pradnya Patil
Clinical Lung Cancer. 2023-09-01
Journal Articles
- The EGFR T790M Mutation Is Acquired Through AICDA-Mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung CancerGregory P Kalemkerian, Khaled A Hassan, Clinical Cancer Research
Press Mentions
Nurturing Integrated Diagnostics in OncologyJanuary 20th, 2022
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerSeptember 24th, 2019- Early Diagnosis and Significant Advances in Treatment Could Reduce High Lung Cancer Death Rate, Says Cleveland Clinic ExpertAugust 1st, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
